Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central anxious procedure, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://smedleym987uwy8.spintheblog.com/profile